<SEC-DOCUMENT>0001493152-22-027872.txt : 20221007
<SEC-HEADER>0001493152-22-027872.hdr.sgml : 20221007
<ACCEPTANCE-DATETIME>20221007085918
ACCESSION NUMBER:		0001493152-22-027872
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221006
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221007
DATE AS OF CHANGE:		20221007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		221299392

	BUSINESS ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:MBOT="http://microbotmedical.com/20221006">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_MBOT_microbotmedical.com_20221006 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20221006_20221006 -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000883975 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityCentralIndexKey">0000883975</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mbot-20221006.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-10-06to2022-10-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-06</xbrli:startDate>
        <xbrli:endDate>2022-10-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20221006__20221006_ztsYwl9dcItl"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_90E_edei--DocumentPeriodEndDate_c20221006__20221006_zi06ACofpr65"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October
6, 2022</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_902_edei--EntityRegistrantName_c20221006__20221006_zFLnTzpi87t9"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityRegistrantName">MICROBOT
MEDICAL INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20221006__20221006_zMNHNJZVm08e"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20221006__20221006_zL5qVsXkuz2d"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityFileNumber">000-19871</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20221006__20221006_zdFam0BhBIGh"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityTaxIdentificationNumber">94-3078125</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20221006__20221006_zBDx7lKKEwq2"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityAddressAddressLine1">25
Recreation Park Drive</ix:nonNumeric></span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,<span id="xdx_90E_edei--EntityAddressAddressLine2_c20221006__20221006_z3er33fWUop2"> <ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityAddressAddressLine2">Unit
108</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20221006__20221006_zhzFhUIjJvdb"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityAddressCityOrTown">Hingham</ix:nonNumeric></span></b></span><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,<span id="xdx_909_edei--EntityAddressStateOrProvince_c20221006__20221006_zNTimYq6F2We">
<ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonNumeric></span></span></b><b> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityAddressPostalZipCode_c20221006__20221006_z8tuYolgXG5d"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:EntityAddressPostalZipCode">02043</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of Principal Executive Offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_90B_edei--CityAreaCode_c20221006__20221006_zseg1KeYLz26"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:CityAreaCode">(781)</ix:nonNumeric></span></b></span><b>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--LocalPhoneNumber_c20221006__20221006_zZ2Ls6JCsJ1j"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:LocalPhoneNumber">875-3605</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
Name or Former Address, if Changed Since Last Report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--WrittenCommunications_c20221006__20221006_zayxe42QcO5g"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--SolicitingMaterial_c20221006__20221006_z50JDw1lpzll"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--PreCommencementTenderOffer_c20221006__20221006_zUkWVLBPV5y9"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20221006__20221006_zDk6YsiPAenf"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20221006__20221006_z5JqRkScl4Qh"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20221006__20221006_z1G4SEFbCkhg"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" name="dei:TradingSymbol">MBOT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--SecurityExchangeName_c20221006__20221006_z1163o4Mdwc8"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>
    </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company <span id="xdx_90C_edei--EntityEmergingGrowthCompany_c20221006__20221006_znMSnEE0YiGa"><ix:nonNumeric contextRef="From2022-10-06to2022-10-06" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 6, 2022 (the &#8220;Closing Date&#8221;), Microbot Medical Inc. (the &#8220;Company&#8221;), through its wholly-owned
subsidiary Microbot Medical Ltd., an Israeli corporation (&#8220;Microbot&#8221;) entered into an Asset Purchase Agreement (the &#8220;Agreement&#8221;)
with Nitiloop Ltd., an Israeli limited liability company (&#8220;Nitiloop&#8221;). Pursuant to the Agreement, on the Closing Date, Microbot
purchased all of Nitiloop&#8217;s rights, title and interest in Nitiloop&#8217;s tangible and intangible assets, including intellectual
property, devices, components and product related materials (the &#8220;Assets&#8221;), but excluding certain excluded assets as described
in the Agreement. The Assets include intellectual property and technology in the field of intraluminal revascularization devices with
anchoring mechanism and integrated microcatheter (the &#8220;Technology&#8221;) and the products or potential products incorporating
the Technology owned by Nitiloop and designated by Nitiloop as &#8220;NovaCross&#8221;, &#8220;NovaCross Xtreme&#8221; and &#8220;NovaCross
BTK&#8221; and any enhancements, modifications and improvements thereof (&#8220;Devices&#8221;). Microbot is not assuming any material
liabilities of Nitiloop other than obligations Nitiloop has to the Israel Innovation Authority and relating to certain renewal/maintenance
fees for a European patent application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the acquisition of the Assets, Microbot shall pay royalties to Nitiloop, which shall not, in the aggregate, exceed
$8,000,000, as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties
    at a rate of 3% of net revenue (as defined in the Agreement) generated as a result of sales, license or other exploitation of the
    Devices; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties
    at a rate of 1.5% of net revenue generated from the sale, license or other exploitation of commercialization of the technology as
    part of an integrated product (as defined in the Agreement).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the royalties set forth in the Agreement and the obligations to the Israel Innovation Authority, Microbot is not required
to pay any additional fees or other consideration to Nitiloop.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Microbot has
the sole discretion in relation to the use, exploitation, management and/or maintenance of the Assets, including whether and/or to what
extent to commercialize and/or to maintain the Assets, the Devices or the intellectual property.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nitiloop made customary representations
and warranties to Microbot, including with respect to authority, title, government financing, licenses and obligations, restrictions
on rights, validity and enforceability, conduct, enforcement, patent office proceedings, fees, no breach and legal action, and anti-bribery
and anti-corruption.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nitiloop agreed to indemnify
Microbot from and against all losses resulting from the inaccuracy or breach of any representation or warranty, the non-fulfillment
or breach of any covenant or agreement of Nitiloop contained in the Agreement or any third-party claims instituted against Microbot
in connection with the period pre-Closing Date. Claims for indemnification are subject to a $50,000 basket and may be satisfied solely
and exclusively by exercise of set-off rights described in the Agreement, other than for fraud or intentional misrepresentation. Indemnification
is further limited by a cap equal to the lesser of (a) royalties actually due to Nitiloop and (b) $1,500,000 or if as a result of certain
misrepresentations, $2,400,000.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Nitiloop and its founding shareholders
agreed to a twenty-four month covenant not to compete with Microbot or develop a product, technology or intellectual property
in the fields of intraluminal revascularization CTO devices and intraluminal robotics.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing is a brief description of the material terms of the Agreement and is qualified in its entirety by reference to the full text
of the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-size: 10pt"><b>Item 8.01.</b></span></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Other Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On October 7, 2022, the Company
issued a press release announcing the Nitiloop acquisition. A copy of the press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K and incorporated herein by reference.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>(d)
Exhibits</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Asset
    Purchase Agreement with Nitiloop, Ltd., dated October 6, 2022</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">99.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex99-1.htm">Press Release</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MICROBOT
    MEDICAL INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Harel Gadot</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
October 7, 2022</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fm0CivTRokWsIkXE12C3EmyzZRN/eiRvadoiLgvLMvPNCDERGW1MjQyXVZHDCZu21h6hwAoZ7RWDI93uEgi3wJtxnrX1w/sDUwoMBmY+lQsdhMH6NA7LBGQ8ixczpUDKRC3huBdRr6dkK1Oi9UbXoG0JR6aWDXrN3Zhw0m+y1HRD1RnZGbIhbhqP8gdULBUc6KlfxHcHeZ6KaDJMJDKmR9vXPJynBtY1NqHLjeh/oy8YfUlK -->

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">Exhibit
10.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSET
PURCHASE AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This ASSET PURCHASE AGREEMENT
(this <B>&ldquo;<I>Agreement</I>&rdquo;</B>) is entered into as of this 6 day of October, 2022 by Nitiloop Ltd., an Israeli
limited liability company (<B>&ldquo;<I>Seller</I>&rdquo;</B>) and Microbot Medical Ltd., an Israeli limited liability company (<B>&ldquo;<I>Purchaser</I>&rdquo;</B>).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Background</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller
    has developed certain intellectual property and technology (including the Patents) in the field of: Intraluminal revascularization
    devices with anchoring mechanism and integrated microcatheter (&ldquo;<B><I>Technology</I></B>&rdquo;), including the Devices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller
    has informed Purchaser of its voluntary cessation of operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    wishes to acquire all rights, title and interest in the Assets (as such term is defined below); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller
    wishes to sell to Purchaser, and Purchaser wishes to purchase from Seller, all right, title and interest in and to the Assets, in
    consideration for the payment by the Purchaser to the Seller of the Royalties (as defined below).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, in consideration of the premises and the covenants and representations set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>1.</I></B></FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>Definitions</I></B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<I>Assets</I>&rdquo;
</B>means all of Seller&rsquo;s tangible and intangible assets (other than the Excluded Assets), including as listed in <U>Exhibit A
</U>of this Agreement, and including but not limited to all Intellectual Property associated thereto (including with respect to the Technology
and the Devices (as defined below)), and all devices, components and product related materials (including, any that were work in progress,
if any). For clarity purposes, the Assets shall also include all design drawings, engineering files, production files and detailed production
and assembly instructions related to the Devices, and all associated regulatory, clinical, Intellectual Property and QA files, in each
case, which are in the possession of the Seller and/or under its control (after reasonable inquiry).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<I>Devices</I>&rdquo;
</B>refer to the following products or potential products incorporating the Technology owned by Seller, and designated by Seller as:
&ldquo;NovaCross&rdquo;, &ldquo;NovaCross Xtreme&rdquo; and &ldquo;NovaCross BTK&rdquo;, and any enhancements, modifications and improvements
thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<I>Disclosure
Schedule</I>&rdquo; </B>means that full and complete list of exceptions related to Seller&rsquo;s representations and warranties, as
set forth in Section 6 hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;Excluded
Assets&rdquo;</B> means (i) all claims for the refund or credit of taxes and other governmental charges of whatever nature arising with
respect to the Assets for all tax periods or portions thereof ending on or prior to the Closing; (ii) all other claims, causes of action,
choses in action, rights of recovery and rights of setoff of any kind, including rights arising under warranties, representations, indemnities
and guarantees made by suppliers of products, services, materials or equipment, or components to the extent related to the period prior
to Closing; (iii) the corporate charter, taxpayer and other identification numbers, seals, minute books, share transfer books, blank
share certificates, and other documents relating to the organization, maintenance, and existence of Seller as a corporation or other
legal entity; (iv) any capital share or other equity of the Seller; (v) any equity interests, cash, cash equivalents, bank accounts or
securities in any other entity owned by Seller or receivables generated prior to Closing; and (vi) any of the rights which accrue or
will accrue to Seller under this Agreement (or under any ancillary agreement between Seller on the one hand and Purchaser on the other
hand entered into at or after the Closing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<I>Executed
Assignments</I>&rdquo;</B> means the executed Assignment of Patent and Trade/Service Marks Rights in the form attached as <U>Exhibit
B,</U> and the additional documents Seller may be required to execute and deliver under Section 5.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Founding
Shareholders</B>&rdquo; means each of Prof. Ran Koronowski and Dvir Keren.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Integrated
Product</B>&rdquo; means any technology, product or device of Purchaser or an affiliate thereof that incorporates or exploits any of
the Technology, other than a Device sold or commercialized on a Standalone Basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Intellectual
Property</I></B>&rdquo; means all intellectual property rights, whether or not patentable, including without limitation, rights in algorithms,
source code, binary code, computer programs, computer software, concepts, confidential information, developments, copyright, data, databases,
designs (whether registered or unregistered), derivative works, discoveries, documents, goodwill, ideas, improvements, inventions, know-how,
object code, original works of authorship, patents, patent applications, processes, proprietary technology, reputation, software, source
code, specifications, statistical models, technology, trade secrets, trademarks, trade dress, trade names and technical information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Liabilities</I></B>&rdquo;
means liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent,
accrued or unaccrued, matured or unmatured or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Net
Revenues</I></B>&rdquo; means all revenues actually received by Purchaser and/or its affiliates that derive from the use, exploitation
or commercialization of the Technology (including without limitation, from the sales or license of Devices on a Standalone Basis or as
part of Integrated Products to non-affiliate third parties) after the deduction of the following deductions, to the extent applicable
to such transactions: (i) sales and value added taxes (excluding any tax on Purchaser&rsquo;s net income), to the extent such amounts
are included in the original gross receipts or are otherwise paid by Purchaser; (ii) any royalties or other similar fees (if any), that
are required to be paid by Purchaser to any third party for the commercialization or sale of the Devices on a Standalone Basis (excluding
for avoidance of doubt any amounts payable to the IIA, which shall not be deducted); (ii) freight, shipping and insurance charges in
respect of such sales to the extent invoiced separately; and (c) credits or allowances actually granted on account of recalls, rejections
or returns of products previously sold as demonstrated by written evidence; provided that with respect to transactions which are not
at arm&rsquo;s length and/or not for cash for such transaction, the term &ldquo;Net Revenues&rdquo; shall mean the total amount that
would have been paid in arms-length transaction according to the current market conditions for such sale or other transaction or according
to market conditions for products similar to the Devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;<I>Patents</I>&rdquo;
</B>means all (a) patents and patent applications listed on <U>Exhibit A</U>; (b) patents or patent applications submitted by or on behalf
of Seller (if any) (i) to which any of the patents listed on <U>Exhibit A</U> expressly claims priority, either directly or indirectly
or (ii) for which any of the patents listed on <U>Exhibit A</U> expressly forms a basis for priority, either directly or indirectly;
and (c) reissues, reexaminations, extensions, continuations, continuations in part, continuing prosecution applications, requests for
continuing examinations, divisions, and registrations of any item in the preceding subparagraph (a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B><I>Royalties</I></B>&rdquo;
shall have the meaning set forth in Section 5.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&ldquo;Standalone
Basis&rdquo; </I></B>means commercialization of a Device in a manner that use thereof is not made as part of another product or device
sold or commercialized by Buyer or an affiliate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 35.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>3.
Closing Conditions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1
<U>Closing</U>. The closing of the sale of the Assets will occur concurrently with the signing of this Agreement, or such other date
as shall be agreed between the Parties, subject to the satisfaction or waiver (as applicable) of all conditions set forth in paragraphs
3.2 and 3.3 (the <B>&ldquo;<I>Closing</I>&rdquo;</B>). The actual time and date when the Closing takes place are herein called the &ldquo;<B><I>Closing
Date</I></B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2
<U>Conditions to Purchaser&rsquo;s obligation to Close</U>. The following are conditions precedent to Purchaser&rsquo;s obligation to
consummate the Closing, any of which may be waived, in writing, exclusively by Purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>IIA Approval</U>. The sale and transfer of the Assets, including the Technology by Seller to Purchaser and the assumption of all Seller&rsquo;s
obligations to the Israeli Innovation Authority (&ldquo;<B><I>IIA</I></B>&rdquo;) by Purchaser, have been approved by IIA in accordance
with the terms set forth in the IIA approval dated June 19, 2022 and such approval remains in full force and effect (&ldquo;<B><I>IIA
Approval</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Compliance with Agreement</U>. Seller shall have performed and complied in all material respects with all of the obligations under
this Agreement that are to be performed or complied with by it on or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Representations and Warranties True</U>. As of the Closing, the representations and warranties of Seller contained in Section 6 shall
be true and correct as at the date hereof and as at the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Patents Not Abandoned</U>. As of the Closing, and subject to the second paragraph of Section 5.3 below, none of the Patents shall
have expired, lapsed, been abandoned or deemed withdrawn and/or subject to any such proceeding that may cause its expiration or invalidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Regulatory Approval</U>. As of the Closing, the approval provided by the FDA for the marketing, distribution and use of the &ldquo;NovaCross&rdquo;
and &ldquo;NovaCross BTK Devices in the United Stated (it being acknowledged by Purchaser that Seller does not possess an FDA approval
for the &ldquo;NovaCross BTK&rdquo; Device and for the NovaCross Xtreme there is an FDA approval, without CTO application) remains in
effect, and, to the extent an assignment or other form of transfer of registration is required, have been duly assigned or transferred
to the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Delivery of Executed Assignments</U>. Seller shall have caused the Executed Assignments to be duly delivered to Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Approvals</U>. The consummation of the transactions contemplated by this Agreement was duly approved by the Board of Directors and
shareholders of Seller, in accordance with Purchaser&rsquo;s charter documents; a copy of said approvals will be provided to Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
Such other customary instruments of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Purchaser,
as may be required to give effect to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 31.5pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3
<U>Conditions to Seller&rsquo;s obligation to Close</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify; text-indent: -0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Compliance with Agreement</U>. Purchaser shall have performed and complied in all material respects with all of the obligations under
this Agreement that are to be performed or complied with by it on or prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify; text-indent: -0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Representations and Warranties True</U>. As of the Closing, the representations and warranties of Purchaser contained in Section 7
are true and correct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify; text-indent: -0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Approvals</U>. The consummation of the transactions contemplated by this Agreement was duly approved by the Board of Directors of
Purchaser, in accordance with Purchaser&rsquo;s charter documents; a copy of said approval will be provided to Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify; text-indent: -0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>IIA Approval</U>. The IIA Approval shall have been duly obtained and shall be in full force and effect on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.45in; text-align: justify; text-indent: -0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>No Injunction</U>. No temporary restraining order, preliminary or permanent injunction or other order issued by any court of competent
jurisdiction or other legal or regulatory restraint or prohibition preventing the consummation of the transactions contemplated hereby
shall be in force provided that none of such orders, injunctions, restraints or prohibitions were sought by or requested by or on behalf
of the Seller or any affiliate, officer, director, manager, member or shareholder of Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4
<U>Termination and Survival</U>. The Parties shall work together and use their best efforts to consummate the Closing as soon as possible.
If despite that Parties&rsquo; good faith efforts, the Closing does not occur by October 31, 2022 (unless extended by mutual consent),
each of Purchaser and Seller may terminate this Agreement by written notice to the other party; provided, however, that neither party
may terminate this Agreement pursuant to this Section 3.4 if the actions or omissions of such party are the cause for the Closing not
having occurred as set forth above. Upon termination, Purchaser will return all documents delivered to Purchaser under this Section 3
to Seller and Seller shall deliver to Purchaser all documents delivered to Seller under this Section 3, and neither party shall have
any claim and/or demand against the other party, its shareholders, directors and/or other officers. The provisions of Section 8 will
survive any termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5
<U>Conduct of Seller Prior to the Closing</U>. Except as contemplated by this Agreement or with the prior written consent of Purchaser,
during the period from the date of this Agreement to the Closing, Seller will not (i) sell, transfer or otherwise dispose of any of its
property or assets or (ii) mortgage or otherwise encumber any of its property or assets, in each case that relate in any way, directly
or indirectly, with any of the Assets. Seller represents and warrants, and Purchaser acknowledges and confirms, that the Company&rsquo;s
business and activities have been terminated, the Company does not and shall not conduct any business and/or operations and does not
have any outstanding employees or consultants nor any commercial activity, and was prepared to undergo voluntary liquidation. Seller
will use all reasonable efforts to preserve intact Seller&rsquo;s assets (including the Assets) and currently existing business organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>4.
Transfer of ASSETs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
<U>Assignment of Assets</U>. Upon the Closing, Seller hereby sells, assigns, transfers, and conveys to Purchaser all right, title and
interest in and to the Assets, free and clear of any third parties&rsquo; rights, liabilities and demands (other than the obligations
to the IIA, which shall be assumed as of the Closing by Purchaser). At the Closing, the Parties will execute and deliver to other Party
the Executed Assignments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
<U>Future Patent Related Submissions</U>. Upon Purchaser&rsquo;s request, Seller shall reasonably cooperate, and shall use reasonable
efforts to cause the inventors of the Assets to cooperate, at the Purchaser&rsquo;s expense, and execute any future submissions of patents
or other registered intellectual property in connection with the Assets, if and to the extent required for their perfection, maintenance
and further developments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
<U>Transfer of Equipment and Other Tangible Assets</U>. Upon the Closing, Seller shall transfer all rights, title and interests and deliver
to Purchaser of any and all equipment and tangible Assets (if any) in the possession of the Seller and/or under its control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
<U>No Liabilities</U>. For the avoidance of doubt, except as may be specifically set forth in this Agreement, Purchaser is not assuming
or acquiring, and shall not be responsible to pay, perform or discharge and Seller is not transferring or assigning, any of Seller&rsquo;s
Liabilities (other than the obligations to the IIA, which shall be assumed as of the Closing by Purchaser). For the avoidance of doubt,
it is clarified and agreed that Purchaser shall be exclusively responsible to pay, perform or discharge any and all Liabilities of any
nature arising out of the Assets relating to the period from and after the Closing (except for matters which are the subject of indemnification
pursuant to Section 6.B) and Seller shall not have any responsibility or liability in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>5.
ROYALTIES PAYABLE TO SELLER AND Additional Obligations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
<U>Royalties</U>. In consideration of the purchase of the Assets, including the Technology, the Devices and associated Intellectual Property
rights, Purchaser shall pay the Seller, royalties as set forth in this Section below, provided that the aggregated royalties payable
by Purchaser shall not exceed US$8,000,000 (eight million US Dollars)(&ldquo;<B><I>Royalties</I>&rdquo; </B>and the &ldquo;<B><I>Purchase
Price Cap</I></B>&rdquo;, respectively):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties
    at a rate of 3% (three percent) of Net Revenue generated as a result of sales, license, or other exploitation or commercialization
    of the Devices (i.e., on a Standalone Basis and not as part of an Integrated Product); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    case of sale, license or other exportation or commercialization of any of Seller&rsquo;s Technology as part of an Integrated Product,
    royalties at a rate of 1.5% of the Net Revenue generated from such Integrated Product.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    shall pay the Royalties on a semi-annual basis within sixty (60) days following each calendar semiannual period for Net Sales in
    the previous semiannual period. Each Royalties payment shall be accompanied by a detailed statement, signed by an officer of the
    Purchaser, of the amount of Net Revenues during the applicable period and such other information as is necessary to determine and
    verify the amount of payments to be made to Seller hereunder. If no Royalties payments are due and payable to Seller in a certain
    calendar year, the Purchaser shall notify Seller in writing to that effect (such notification to be signed by an officer of the Purchaser),
    within 60 days following the end of such calendar year. The foregoing report will, subject to confidentiality restrictions, include,
    inter alia, the sales of the Devices and/or Integrated Devices made by Purchaser (or any of its affiliates) with a breakdown of the
    Net Revenues according to country, identity of customers, currency of sales, number and type of Devices sold and applicable deductions.
    All Royalty payments payable to Seller shall be paid in the currency paid to Purchaser. VAT shall be added to the Royalties payable
    hereunder by Purchaser, as and if required pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
    shall keep full and accurate books and records of all items necessary to correctly calculate the payments due to Seller hereunder
    for the latest four (4) calendar years. Within 6 months after the end of each fiscal year, Purchaser shall provide Seller with a
    report, certified by its independent auditor stating all amounts due to Seller hereunder in the reported year. Purchaser shall have
    audit rights with respect to the calculation of any Royalties payments that are made under this Agreement. Accordingly, upon the
    request of Seller, and not more than once in any twelve (12) month period, Purchaser shall permit (and shall ensure that its affiliates
    permit) an independent public accounting firm reasonably acceptable to Purchaser engaged by Seller to examine such books and records
    (insofar as they relate to such payments) during normal business hours, on reasonable prior written notice, to audit Purchaser&rsquo;s
    (and its Affiliates&rsquo;) Net Revenues as utilized to calculate the Royalty payments due to Seller hereunder; provided, however,
    that such independent accountants shall not disclose Purchaser&rsquo;s (or its affiliates&rsquo;) confidential information to Seller,
    except to the extent such disclosure is necessary to verify the amount of payments due hereunder. If such accounting firm concludes
    that Royalty payments have been underpaid, then, unless Purchaser&rsquo;s independent accounting firm disagrees with such conclusion,
    Purchaser shall pay, within thirty (30) days of the date that Seller advises Purchaser in writing of such unpaid Royalty payments,
    all such unpaid Royalty payments, plus interest at a rate of the U.S. Prime Rate, as reported in The Wall Street Journal, Eastern
    Edition, for the period between such unpaid Royalty payments should have been paid until such amounts are actually paid. All expenses
    relating to such audit shall be borne by Seller, unless such audit discloses an underpayment is equal to or exceeds five percent
    (5%) with respect to a Royalties payment calculation, in which case such expenses shall be paid by Purchaser.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    than the Royalties specified in this Section 5.1 above, no additional fees or other consideration shall be payable to Seller and
    no consideration is payable to any shareholders of Seller.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
    hereby agree that Purchaser shall have the sole discretion in relation to the use, exploitation, management and/or maintenance of
    the Assets, including whether and/or to what extent to commercialize and/or to maintain the Assets, the Devices or the Intellectual
    Property; provided, however, that Purchaser confirms that to its good faith estimation as at the date of this Agreement and as of
    the Closing, Purchaser has good faith intention to commercialize the Assets, subject to, among other things, the performance of further
    examination of the Technology, the Devices, the Intellectual Property and the market opportunities, as well as availability of funds
    to do so. In furtherance of the foregoing, (i) Purchaser will not have any claim and/or demand against Seller and/or any of its shareholders
    and/or directors and/or officers in relation to Purchaser&rsquo;s management and/or maintenance of the Assets, including any action
    and/or omission of Purchaser in relation thereto, (ii) Purchaser will not have any liability or obligation for the payment of Royalties
    or any other monetary obligation to Seller and/or its shareholders if it does not or cannot so commercialize the Technology, the
    Devices and/or the Intellectual Property, whether as a Standalone Basis or as part of an Integrated Product; and (iii) without derogating
    from the aforesaid, it is agreed that Purchaser shall have the sole discretion in respect of the management of the Patents or other
    Intellectual Property.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
<U>Further Cooperation</U>. Following the Closing, Seller and Purchaser will execute and deliver such other instruments and do and perform
such other acts and things that are reasonably necessary for effecting the consummation of the transactions contemplated hereby, including,
without limitation, execution, acknowledgment, and recordation of such other papers, and using commercially reasonable efforts to obtain
the same from the respective inventors, as necessary for perfecting and conveying unto Purchaser the benefit of the transactions contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
<U>Payment of Fees</U>. Except as provided in the second paragraph below, Seller will pay any maintenance fees, annuities, and the like
due or payable on the Patents (if any) until the Closing and Purchaser shall pay all such fees due only following Closing, to the extent
Purchaser would like to continue their maintenance (at Purchaser&rsquo;s sole discretion). Notwithstanding anything to the contrary herein,
it is acknowledged by the parties that European Patent Application No. 12735054.4 of the Seller has expired due to the non-payment of
the renewal/maintenance fees, but may be restored if such renewal/maintenance fees in the amount of approximately NIS12,000 are paid
not later than November 23, 2022. Purchaser shall bear and pay such renewal/maintenance fees and Seller shall have no liability in connection
therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4
<U>Foreign Assignments</U>. To the extent the Patents include non-United States patents, Seller will deliver to Purchaser&rsquo;s representatives
executed documents in a form as may be required in the non-U.S jurisdiction in order to perfect the assignment to Purchaser of the non-U.S.
patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.5
<U>Non-Compete</U>. During a period of twenty four (24) months as of the Closing, Seller and/or its Founding Shareholders shall not (directly
or indirectly) compete with Purchaser or develop another product, technology or Intellectual Property, in each case, in the fields of
intraluminal revascularization CTO devices and intraluminal robotics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.6
<U>Case of Disposition</U>. Purchaser shall not, and undertakes to ensure that any of its affiliates shall not directly sell, assign
or transfer, any of the Assets, as a standalone transaction (i.e, not as part of the sale of all material part of Purchaser&rsquo;s assets
or stock), unless: (i) a prior written notice of such sale, assignment, or transfer is rendered by Purchaser to Seller, including details
regarding the identity of such prospective purchaser, (ii) such purchaser undertakes in writing towards the Seller to assume and be bound
by all of Seller&rsquo;s obligations under this Agreement and (iii) Seller shall be eligible to receive 50% of any and all consideration
(if any) actually paid or provided by the prospective purchaser to the Purchaser for the Assets, but in any case, not to exceed (together
with any previous paid Royalties) the Purchase Cap Price. It is clarified that that nothing in the foregoing shall be deemed to prevent
or limit the Purchaser, in any way, from (and shall not require the consent of Seller to): (i) selling, assigning or transferring the
Assets as part of a transaction for a sale of the Purchaser (whether by way of a merger, consolidation, sale of all or substantially
all of Purchaser&rsquo;s assets, change of control, or similar transaction) (&ldquo;<B>Purchaser&rsquo;s Deemed Liquidation Event</B>&rdquo;),
provided that in such case the prospective purchaser undertakes in writing for the benefit of Seller to assume and be bound by all of
Purchaser&rsquo;s obligations under this agreement; or (ii) selling and/or issuing securities of Purchaser, including the sale of all
or substantially all of Purchaser&rsquo;s shares, in which case this Agreement shall remain in effect, in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>6.
Representations and Warranties of Seller</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller
hereby represents and warrants to Purchaser as follows; <U>provided</U>, that the representations and warranties made as of the date
hereof shall be deemed to be qualified by the disclosure schedule attached hereto as <B><U>Exhibit C </U></B>(the &ldquo;<B><I>Disclosure
Schedule</I></B>&rdquo;):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1
<U>Authority</U>. Seller is a limited liability company duly formed and validly existing under the laws of State of Israel. Seller has
the full power and authority and has obtained all corporate and third party consents, approvals, and/or other authorizations required
to enter into this Agreement and to carry out its obligations hereunder, including, without limitation, the assignment and sale of the
Assets to Purchaser. This Agreement, including all exhibits, annexes and schedules, when executed and delivered by Seller, will constitute
the valid, binding and enforceable obligations of Seller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2
<U>Title and Contest</U>. Seller owns all right, title and interest to the Assets, including, without limitation, all right, title and
interest to sue for infringement of the Patents. The Patents are free and clear of all liens, claims, mortgages, pledges, security interests
or other encumbrances and restrictions of any kind whatsoever (other than such deriving from the IIA funding pursuant to applicable law).
The Seller and the Founding Shareholders are not aware of any written notice or other written evidence pursuant to which the Patents
or the Devices breach any third party intellectual property rights. The Seller is not party to any contract, agreement, option, commitment,
proposal, bid, offer, or right with, to, or in any person to commercialize and/or manufacture and/or market and/or distribute products
based on the Assets. To Seller&rsquo;s knowledge, without conducting a freedom to operate search, the Assets do not infringe any third
parties&rsquo; rights, including, but not limited to, patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3
<U>Government Financing</U>. Other than as set forth in <U>Schedule 6.3</U> of the Disclosure Schedule, none of the Seller, its predecessors,
affiliates, founders or inventors of any of the Patents, has obtained or received any funding, benefits or grants from the IIA or any
other governmental authority and/or other quasi-governmental institution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.4
<U>Existing Licenses, Agreements and Obligations</U>. No licenses or other rights under the Assets, including, but not limited to, the
Assets, have been granted to or retained by Seller and after Closing, Seller and/or any of its shareholders will not retain any rights
or interest in the Assets (other than to receive Royalties according to the provisions of this Agreement). The Seller is not engaged
in or a party to any outstanding agreements currently in effect relating to the Assets, including with any customers, suppliers, employees
or consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.5
<U>Restrictions on Rights</U>. Purchaser will not be subject to any covenant not to sue or similar restrictions on its enforcement or
enjoyment of the Assets as a result of any prior transaction related to the Assets to which Seller, Seller&rsquo;s affiliates, or any
inventor is a party. To Seller&rsquo;s best knowledge, Purchaser will not be subject to any covenant not to sue or similar restrictions
on its enforcement or enjoyment of the Assets as a result of any prior transaction related to the Assets to which any non-inventor assignor
to Seller or Seller&rsquo;s affiliates is a party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.6
<U>Validity and Enforceability</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Assets include all Intellectual Property of Seller (including all outstanding patents and patent applications registered in the name
of or submitted by Seller).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Seller has never been notified that any of the Patents has been found invalid, unpatentable, or unenforceable for any reason in any
inter parties administrative, arbitration, judicial, or other proceeding, with the exception of rejections, objections, or other deficiencies
identified by a patent authority or patent office which were overcome to result in the allowance, grant, or patenting of such claimed
subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Seller has not received any written notice from any source suggesting the invalidity and/or possible invalidity, unpatentability, or
unenforceability of any claimed subject matter within the Patents that has ultimately been allowed, granted, or otherwise deemed patentable
by a respective patent authority or patent office, with the exception of rejections, objections, or other deficiencies identified by
such patent authority or patent office which were overcome to result in the allowance, grant, or patenting of such claimed subject matter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.7
<U>Conduct</U>. Other than as expressly set forth in <U>Schedule 6.7 of the Disclosure Schedule,</U> Seller has not engaged in any conduct,
or omitted to perform any necessary act, the result of which would be reasonably expected to invalidate any of the Patents or hinder
their enforcement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.8
<U>Enforcement</U>. Seller has not initiated any enforcement action with respect to any of the Patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.9
<U>Patent Office Proceedings</U>. To Seller&rsquo;s knowledge, (a) none of the Patents have been or are currently involved in any reexamination,
reissue, interference proceeding or any similar proceeding and (b) no such proceedings are pending or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.10
<U>Fees</U>. Other than as expressly set forth in <U>Schedule 6.7</U> of the Disclosure Schedule, all maintenance fees, annuities, and
the like due or payable on the Patents have been timely paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.11
<U>No Breach and No Legal Action</U>. Neither the execution and delivery of this Agreement nor compliance by the Seller with the terms
and provisions hereof will conflict with, or result in a breach or violation of, any of the terms, conditions and provisions of: (i)
the Seller&rsquo;s articles of association, (ii) any judgment, order, injunction, writ, decree, or ruling of any court or governmental
department, commission, board, bureau, agency, or authority, domestic or foreign to which Seller and/or to its knowledge, its shareholders
and/or officers are subject, (iii) any material agreement, contract, lease, license or commitment to which the Seller is a party or to
which it is subject, or (iv) applicable law, statute, ordinance or regulation. Such execution, delivery and compliance will not (a) give
to others any rights, including rights of termination, cancellation or acceleration, in or with respect to any material agreement, contract,
lease, license or commitment referred to in this paragraph, or to any of the Assets, or (b) otherwise require the consent or approval
of any person, which consent or approval has not heretofore been obtained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, as of date of signing of this Agreement, there is no pending or threatened action by or against the Seller and/or, to Seller&rsquo;s
knowledge, by or against its shareholders and/or directors and/or officers that relate to the Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.12
<U>Waiver and Release</U>. If and to the extent requested by Purchaser, at Purchaser&rsquo;s sole discretion, Seller hereby irrevocably
provides Purchaser with the consent to engage former employees and/or service providers of Seller (the &ldquo;<U>Engagement</U>&rdquo;);
and Seller and/or its affiliates, directors, officers and shareholders have and/or will have no claims and/or demands against Purchaser,
its shareholders, directors, officers and employees in connection with the Engagement, directly or indirectly. The Seller is not aware
of any limitation and/or restriction that prohibits and/or may otherwise restrict Purchaser from entering into an Engagement. For the
avoidance of doubt, it is clarified that Seller assumes no responsibility or liability in connection with any Engagement or the success
thereof, and any such Engagement shall be subject to its acceptance by any such former employees and/or service providers of Seller that
Purchaser wishes to engage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.13
<U>Executed Assignments</U>. The Executed Assignments, upon the execution thereof, are binding, unconditional and irrevocable, other
than as expressly stated therein, and enforceable by Purchaser. Seller, after making all required inquiries, is not aware of any claim,
demand and/or liability that might be imposed on Purchaser in connection with the assignment of the Executed Assignments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.14
<U>Anti-Bribery and Anti-Corruption</U>. Seller, including any of its officers, directors, employees, agents, and representatives, have
not, to Seller&rsquo;s best knowledge: (i) taken any action, directly or indirectly, that violated any applicable anti-corruption laws
and regulations; (ii) made any offer, payment, or promise, or authorized the offer, payment or promise, of any money or other property,
gift, or anything of value, regardless of form, directly or indirectly, to any government official for purposes of influencing any act
or decision of such government official in his or her official capacity to secure an improper advantage, obtain or retain business or
direct business to any person or away from any person, in each case, in violation of applicable law; (iii) accepted or received any unlawful
contributions, payments, gifts, or expenditures in connection with the Assets; or (iv) been under administrative, regulatory, civil or
criminal investigation, indictment, audit or internal investigation with respect to any suspected, alleged or actual violation of any
anti-corruption law, and Seller is not aware of any circumstances reasonably likely to give rise to such action or investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.15
<U>Subsidiaries</U>. Seller does not have any subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>6.A.
Representations and Warranties of Purchaser</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchaser
hereby represents and warrants to Seller as follows<B>:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.A.1
<U>Authority</U>. Purchaser is a limited liability company duly formed and validly existing under the laws of State of Israel. Purchaser
has the full power and authority and except for the IIA Approval or as contemplated in this Agreement, has obtained all corporate and
third party consents, approvals, and/or other authorizations required to enter into this Agreement and to carry out its obligations hereunder,
including, without limitation, the purchase of the Assets from Seller. This Agreement, including all exhibits, annexes and schedules,
when executed and delivered by Purchaser, will constitute the valid, binding and enforceable obligations of Purchaser, except as may
be limited by bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting creditors&rsquo; rights generally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.A.2
<U>No Breach and No Legal Action</U>. Neither the execution and delivery of this Agreement nor compliance by the Purchaser with the terms
and provisions hereof will conflict with, or result in a breach or violation of, any of the terms, conditions and provisions of: (i)
the Purchaser&rsquo;s articles of association, (ii) any judgment, order, injunction, writ, decree, or ruling of any court or governmental
department, commission, board, bureau, agency, or authority, domestic or foreign to which Purchaser is subject, (iii) any material agreement,
contract, lease, license or commitment to which the Purchaser is a party or to which it is subject, or (iv) applicable law, statute,
ordinance or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.A.3
<U>Approvals</U>. No approval by any individual or entity, including without limitation any governmental authority or other third party,
is required in connection with the execution, delivery or performance of this Agreement or the transaction documents or the consummation
by the Purchaser of the transactions contemplated herein and therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.A.4
<U>Receipt of Information</U>. Purchaser acknowledges that it has been furnished by Seller with information regarding the Seller, the
business of the Seller and the Assets which it has requested, and has been afforded the opportunity to ask questions of, and receive
answers from, duly authorized officers or other representatives of Seller concerning various matters relating to the Seller, the business
of the Seller and the Assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.B.
<FONT STYLE="text-transform: uppercase"><B><I>Indemnification BY SELLER</I></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to the provisions of this Section 6.B., Purchaser and its representatives and successors shall be indemnified, defended and held
harmless by Seller from and against all Losses (as such term is defined below) suffered or incurred by Purchaser, its successors, officers
and/or stockholders (collectively: &ldquo;<B><I>Purchaser Affiliates</I></B>&rdquo;) by reason of, arising out of or resulting from:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the inaccuracy or breach of any representation or warranty of Seller contained in or made pursuant to this Agreement, any Schedule or
any certificate delivered by the Seller pursuant to this Agreement with respect hereto or thereto in connection with the Closing; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
the non-fulfillment or breach of any covenant or agreement of the Seller contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
any third parties&rsquo; claim instituted against Purchaser in connection with the conduct of Seller&rsquo;s business and/or use of the
Assets, in each case, to the extent relating to the period prior to the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
As used in this Section 6.B., the term &ldquo;<B>Losses</B>&rdquo; shall include all losses, liabilities, damages, judgments, awards,
orders, penalties, settlements, costs and expenses (including, without limitation, interest, penalties, court costs and reasonable legal
fees and expenses) including those arising from any demands, claims, suits, actions, costs of investigation, notices of violation or
noncompliance, causes of action, proceedings and assessments whether or not made by third parties or whether or not ultimately determined
to be valid. Notwithstanding anything else contained in this Agreement, under no circumstances shall an indemnified party be entitled
to indemnification in connection with Losses that are indirect, consequential or punitive unless Losses that are indirect, consequential
punitive are actually awarded to a third party by a court of competent jurisdiction and are paid by an Indemnified Person (as defined
below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Subject to the limitations and provisions set forth in this <U>Section 6.B</U>, upon receipt by Seller (the &ldquo;<B><I><U>Indemnifying
Person</U></I>&rdquo;</B>) of a certificate signed by any officer (an &ldquo;<B><I><U>Officer&rsquo;s Certificate</U></I></B>&rdquo;)
of Purchaser Affiliate (an &ldquo;<B><I><U>Indemnified Person</U></I></B>&rdquo;) stating that Losses exist with respect to the indemnification
obligations set forth in <U>Section 6.B</U>, and specifying in reasonable detail the Losses so stated (the &ldquo;<B><I><U>Claimed Amount</U></I></B>&rdquo;)
and the underlying circumstances, the Indemnified Person shall, subject to the provisions of this <U>Section 6.B</U>, be entitled to
be indemnified in accordance with this <U>Section 6.B</U>. The Indemnifying Person shall have a period of thirty (30) days from and after
delivery of any Officer&rsquo;s Certificate to deliver to the Indemnified Person a response, in which the Indemnifying Person shall:
(i) agree that the Indemnified Person is entitled to receive payment for all of the requested Losses or (ii) dispute that the Indemnified
Person is entitled to receive payment for all the requested Losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
In respect of any third party claim that is subject of a claim by an Indemnified Person for indemnification under this <U>Section 6.B
</U>(a &ldquo;<B><U>Third Party Claim</U></B>&rdquo;), the Indemnified Person shall, without qualification of the right to the Indemnified
Person to be indemnified for indemnifiable Losses incurred in connection with such Third Party Claim, control the defense of the Third
Party Claim and shall be entitled to appoint counsel for such defense (such counsel to be reasonably acceptable to the Indemnifying Person)
and shall promptly inform the Indemnifying Person upon receipt of a Third Party Claim; provided, however, that no delay in providing
such notice shall affect an Indemnified Person&rsquo;s rights hereunder, unless (and then only to the extent that) the Indemnifying Person
is materially prejudiced thereby. No Indemnified Person shall consent to the entry of any judgment or enter into any settlement or resolution
of such Third Party Claim without the consent of the Indemnifying Person, such consent not to be unreasonably withheld, conditioned or
delayed. The Indemnifying Person shall have the right to participate at its own expense in the defense of the liability asserted therein.
The Indemnified Person shall furnish or cause to be furnished to the Indemnifying Person copies of all material correspondence exchanged
between the Indemnified Person and the applicable third party, as well as copies of all pleadings, responsive pleadings, motions and
other similar legal documents and papers received or filed in connection the Third Party Claim. The Parties hereto agree to reasonably
cooperate with each other in connection with the defense, negotiation or settlement of any Third Party Claim, including by attending
such conferences, discovery proceedings, hearings, trials or appeals as may be reasonably requested in connection therewith and providing
reasonable access to each other&rsquo;s relevant business records and other documents and employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Limitations on Indemnity.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Survival of Representations and Warranties and Covenants</U>. Other than in case of fraud or intentional misrepresentation, all the
representations and warranties of Seller contained in <U>Section 6</U> shall survive the Closing hereunder and shall continue in full
force and effect after such Closing for a period of twenty four (24) months after the Closing, after which they shall automatically expire,
provided that any representation or warranty in respect of which indemnity may be sought hereunder, and the right of indemnity with respect
thereto, shall survive the time at which it would otherwise terminate pursuant to this Section 6B if notice of the inaccuracy or breach
or potential inaccuracy or breach thereof giving rise to such right or potential right of indemnity shall have been given to the Seller
prior to such time; All covenants and agreements set forth herein shall survive the Closing for the period specified for their respective
terms or, if no such period is specified therein, for the maximum time period permitted under applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Sources of Recovery by Purchaser Affiliates. Recovery by the Purchaser Affiliates with respect to claims for indemnification pursuant
to Section 6.B shall be subject to the caps set forth in Section 6.B(e)(v) below and may be satisfied solely and exclusively by exercise
of the Setoff Rights set forth in Section 6.B(e)(iv)other than in case of fraud or intentional misrepresentation. Purchaser shall not
have any rights to set off or deduct amounts due under this Agreement, except in accordance with the Setoff Rights.<B><I><U>]</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Notwithstanding anything to the contrary set forth in this Agreement, the Indemnifying Person shall not be required to indemnify the
Indemnified Person for Losses until and unless the aggregate amount of all such Losses exceeds US$50,000 (the <B>&ldquo;<I>Indemnification
Threshold</I>&rdquo;</B>), and if the aggregate of all Losses exceeds the Indemnification Threshold, then the Indemnified Person shall,
to the extent that it is otherwise entitled to be indemnified pursuant to this Section 6.B, be entitled to indemnification for all Losses,
subject to the other limitations set forth in this Section 6.B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Notwithstanding anything to the contrary, Purchaser Affiliates sole and exclusive source of recovery of Losses from Seller for the purpose
of any indemnification rights provided herein shall be through set off from any Royalties actually due and payable to Seller, to the
extent due (including through restitution of any Royalties previously received (if any) by Seller, other than in case of willful misrepresentation
or fraud (the &ldquo;<B>Setoff Rights</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Caps on Indemnification by Seller</U>. Without derogating from Section 6.B(iv), and other than in case of fraud or willful misrepresentation,
in no event shall the Purchaser Affiliates be entitled to recover Losses for claims for indemnification pursuant to <U>Section 6.B</U>,
in excess of the lesser of: (a) the amount of Royalties actually due to the Seller according to this Agreement, and (b) an aggregate
amount of US$1,500,000, unless and to the extent that the Losses derive from IP misrepresentation, in which case, the limitation under
this clause (b) shall be an aggregate amount of US$2,400,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
<U>Exclusive Remedy</U>. The provisions contained in this Article 6.B are intended to provide the sole and exclusive remedy for the Buyer
Affiliates and Seller Affiliates following the Closing as to all Losses based on, arising out of or relating to this Agreement (it being
understood that nothing in this Section 6.B or elsewhere in this Agreement shall affect the parties&rsquo; rights to specific performance
or other equitable remedies to enforce the parties&rsquo; obligations under this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B><I>7.
Miscellaneous</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
<U>Required Disclosure and Confidentiality</U>. The Seller acknowledges and agrees that the Purchaser has disclosure obligations under
(a) the United States Securities Act of 1933, as amended and the United States Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder and (b) the listing requirements of the Nasdaq Capital Market; and accordingly, the Purchaser
shall (x) publicly disclose the terms and existence of this Agreement and the identities of the parties hereto, (y) publicly file a true
and correct copy of this Agreement with the United States Securities and Exchange Commission and (z) otherwise divulge any or all of
the terms and conditions of this Agreement to any third party to comply with securities and/or listing laws, rules and regulations applicable
to it. Seller confirms and undertakes to keep confidential and not to disclose or make available to any third party any information related
to the Parties&rsquo; discussions and/or in connection with the Assets, other than disclosures required to obtain approvals for the transactions
contemplated hereby, disclosures to shareholders of the Seller (who are bound by confidentiality no less strict than as set in this Agreement)
and those professionals and advisors who have a reasonable need to know, disclosures of information already available to the public or
any other disclosures required by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
<U>Governing Law; Venue/Jurisdiction</U>. This Agreement will be interpreted, construed, and enforced in all respects in accordance with
the laws of the State of Israel, without reference to its choice of law principles to the contrary. Each party irrevocably consents to
the exclusive jurisdiction and venue of the courts located in Tel Aviv, Israel in connection with any action, suit, proceeding, or claim
arising under or by reason of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
<U>Notices.</U> All notices and other communications required or permitted hereunder to be given to a party to this Agreement shall be
in writing and shall be telecopied, emailed or sent by courier, or otherwise delivered by hand, addressed to such party&rsquo;s address
as set forth below or at such other address as the party shall have furnished to each other party in writing. Notices to Seller are to
be sent to: If to Seller, to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nitiloop
Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4
Carmeli Street, Ramat Gan</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Irit Yaniv, Chairman</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
<U>irit@almedaventures.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy (which shall not constitute notice) to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amit,
Pollak, Matalon &amp; Co.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Ian Rostowsky, Adv.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APM
House, 18 Raoul Wallenberg St.,Tel Aviv 6971915, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-mail:
<U>Ianr@apm.law</U>;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
if to Purchaser, to:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hayozma
6, Yokneam Illit, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Harel Gadot, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
: harel@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cc:
Rachel Vaknin, CFO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
: rachel@microbotmedical.comAny notice sent in accordance with this Section 7.3 shall be effective (i) if sent by courier - two (2) business
days after delivery to the courier service, (ii) if sent by messenger, upon delivery to the addressee, and (iii) if sent via facsimile
or email- upon transmission and confirmation of receipt, or, if transmitted and received on a non-business day, on the first business
day following transmission and confirmation of receipt (provided, however, that any notice of change of address shall only be valid upon
receipt). Irit Yaniv (the &ldquo;<B>Seller Representative</B>&rdquo;) shall serve as the sole representative and focal point on behalf
of Seller vis-&agrave;-vis the Purchaser for any purpose or matter under this Agreement, and any notice, action or resolution required
to be taken by the Seller under this Agreement shall be addressed to Irit Yaniv.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4
<U>Relationship of Parties</U>. The parties hereto are independent contractors. Nothing in this Agreement will be construed to create
a partnership, joint venture, franchise, fiduciary, employment or agency relationship between the parties. Neither party has any express
or implied authority to assume or create any obligations on behalf of the other or to bind the other to any contract, agreement or undertaking
with any third party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5
<U>Severability</U>. If any provision of this Agreement is found to be invalid or unenforceable, then the remainder of this Agreement
will have full force and effect, and the invalid provision will be modified, or partially enforced, to the maximum extent permitted to
effectuate the original objective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6
<U>Waiver</U>. Failure by either party to enforce any term of this Agreement will not be deemed a waiver of future enforcement of that
or any other term in this Agreement or any other agreement that may be in place between the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7
<U>Taxes</U>. Each party shall be solely responsible of and bear any and all taxes applicable to such party. To the extent required under
applicable law, Purchaser shall be entitled to deduct and withhold from any amounts payable pursuant to this Agreement such amounts as
may be required to be deducted or withheld therefrom under applicable law and to remit such amounts to the applicable governmental authority.
Purchaser shall duly honor any valid tax reduction or exemption certificate provided by Seller. To the extent that such amounts are so
deducted or withheld, such amounts shall be treated for all purposes under this Agreement as having been paid to the person to whom such
amounts would otherwise have been paid and Purchaser shall provide the Seller with reasonable evidence of the withholding and remittance
of such tax by the Purchaser.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8
<U>Miscellaneous</U>. Each Party shall bear its own legal and other professional fees and expenses incurred regarding the execution,
delivery and closing of this Agreement and the transactions contemplated hereby. This Agreement, including its exhibits and any other
written instruments contemplated herein or hereby, constitutes the entire agreement between the parties with respect to the subject matter
hereof and thereof and supersedes all prior agreements, understandings, negotiations, and discussions solely with respect to the subject
matter hereof. Neither of the parties will be bound by any conditions, definitions, warranties, understandings, or representations with
respect to the subject matter hereof other than as expressly provided herein except as set forth in any written agreements or side letters
executed by the parties concurrently with the execution of this Agreement. The section headings contained in this Agreement are for reference
purposes only and will not affect in any way the meaning or interpretation of this Agreement. This Agreement is not intended to confer
any right or benefit on any third party (including, but not limited to, any employee or beneficiary of any party), and no action may
be commenced or prosecuted against a party by any third party claiming as a third-party beneficiary of this Agreement or any of the transactions
contemplated by this Agreement<B>. </B>No oral explanation or oral information by either party hereto will alter the meaning or interpretation
of this Agreement. No amendments or modifications will be effective unless in writing signed by an authorized representative of each
of the parties. None of the rights, privileges, or obligations set forth in, arising under, or created by this Agreement may be assigned
or transferred by either party without the prior consent in writing of the other party to this Agreement. Notwithstanding the aforesaid,
(a) the Seller shall have the right to assign any of its right to receive Royalties to any of its shareholders and/or to a trustee appointed
by the Seller or its shareholders for such purpose, by the delivery of a written notice to the Purchaser and further that any and all
payments are paid by the Purchaser to a trustee appointed for such purpose by Seller (the identity of which shall be as notified by the
Seller Representative) who shall be solely responsible for such payments&rsquo; disbursal (it being clarified, however, that any such
assignment shall not relieve the Seller from its indemnification obligations hereunder through Purchaser&rsquo;s Setoff Rights which
shall remain in full force and effect, and accordingly Purchaser may withhold payments to any such appointed trustee pursuant and subject
to the terms of this Agreement and the Setoff Rights); and (b) Purchaser shall be entitled to assign and/or transfer this Agreement and/or
any of the Assets to (i) its affiliates, provided that the Purchaser informs Seller in advance and writing regarding such assignment,
such affiliate undertakes in writing for the benefit of Seller to assume and be bound by the obligations of this agreement, and Seller
shall remain liable for the performance of such obligations by affiliate, and/or (ii) an acquirer in case of a Purchaser&rsquo;s Deemed
Liquidation Event upon the terms set forth in section 5.6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.9
<U>Counterparts</U>. This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together
constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
witness whereof, intending to be legally bound, the parties have executed this Asset Purchase Agreement as of the Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SELLER</U>:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PURCHASER</U>:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NITILOOP
    LTD.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MICROBOT
    MEDICAL LTD.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Irit Yaniv</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Harel Gadot</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irit
    Yaniv</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairperson</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    CEO and Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
the Founding Shareholders, each severally, in our personal capacity (and not in the name of the Company) hereby provide our consent to
be bound by and comply with Section 4.2, the non-compete undertakings set forth in Section 5.5 of this Agreement and the representation
made under the third sentence of Section 6.2:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RAN
    KORONOWSKI:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>DVIR <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KEREN:</FONT></B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Ran Kornowski</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Dvir Keren</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ran
    Kornowski</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dvir
    Keren</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    &ndash; Cadiology</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">Co-Founder-Nitiloop</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 87px; width: 225px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Microbot
Medical Strengthens LIBERTY<SUP>&reg;</SUP> Robotic System Portfolio with Acquisition of Novel FDA-Cleared Devices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Integration
with the LIBERTY<SUP>&reg;</SUP> Robotic System &amp; One &amp; Done&trade; Technology May Enable Future Acceleration of Robotic
Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market<SUP>1</SUP>
through the Expansion of Robotic Ecosystem for Endovascular Procedures</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HINGHAM,
Mass., October 7, 2022</B> &ndash; Microbot Medical Inc. (Nasdaq: MBOT) announced today, as a continuation of its recent regulatory and
future commercialization activities, together with its strategic mission to enable accessibility to multiple endovascular procedures
globally, that it has acquired the assets of privately-held Nitiloop Ltd. The acquisition includes the NovaCross&trade; family of Microcatheters
(NovaCross CTO, NovaCross Xtreme and NovaCross BTK), a U.S. Food and Drug Administration (FDA) cleared family of medical devices intended
to facilitate the intraluminal placement of conventional and steerable guidewires beyond stenotic lesions, including chronic total occlusions
(CTO), prior to PTCA or stent intervention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
NovaCross&trade; Microcatheter family, as a standalone device or when potentially integrated with the Company&rsquo;s One &amp; Done&trade;
technology, is expected to create a collection of procedure related kits that are customized for the LIBERTY&trade; Robotic System. The
LIBERTY<SUP>&reg;</SUP> Robotic System is the first-ever disposable endovascular robotic system with remote operation capabilities
and small footprint designed to reduce the requirement of capital investment and Cath Lab space. The Company expects this integration
to help revolutionize and standardize the way endovascular procedures are conducted, while eliminating barriers to access and increasing
the adoption rate of robotics in the endovascular space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
integration of technologies, such as the NovaCross&trade; Microcatheter family, fits well with the ecosystem strategy of the Company
by allowing it to be competitive in the robotic as well as the instruments market for endovascular procedures, with the aim to integrate
imaging and big data capabilities in the future. The Company believes the achievement of the LIBERTY Robotic System ecosystem will allow
Microbot Medical to advance the adoption of robotics in the endovascular space, globally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The
addition of Nitiloop&rsquo;s innovative, FDA cleared microcatheter family complements the unique robotic ecosystem we are establishing
for endovascular procedures. This is expected to further assist us in executing our strategic plan of becoming a complete procedure-based
company, allowing Microbot Medical to be competitive across the entire endovascular robotic space,&rdquo; commented Harel Gadot, Chairman,
President and CEO. &ldquo;We believe the NovaCross&trade; family of products, once integrated into our existing technology platforms
with the LIBERTY Robotic System and our future One &amp; Done technology, will potentially standardize endovascular procedures globally
and may finally allow accessibility to robotic technology for the millions that are in dire need of life-saving treatment.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
The Insight Partners market research study titled &lsquo;Chronic total occlusion Market&rsquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Microbot Medical</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot&rsquo;s current proprietary technological platforms
provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for
patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available
at http://www.microbotmedical.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safe
Harbor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities
for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or
prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that
contain words such as &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects&rdquo;
and &ldquo;estimates&rdquo;) should also be considered to be forward-looking statements. Forward-looking statements involve risks and
uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of potential
products, including LIBERTY and NovaCross&trade; Microcatheter family, the outcome of its studies to evaluate the Company&rsquo;s other
existing and future technologies, any failure or inability to recruit physicians and clinicians to serve as primary investigators to
conduct the Company&rsquo;s Self-Cleaning Shunt&rsquo;s early feasibility study which could adversely affect or delay such study, uncertainty
in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, the failure or inability to integrate
the NovaCross&trade; Microcatheter family, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital,
and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading
&ldquo;Risk Factors&rdquo; in Microbot Medical&rsquo;s periodic reports filed with the Securities and Exchange Commission (SEC), which
are available on the SEC&rsquo;s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking
statements, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
Polyviou</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EVC
Group</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mpolyviou@evcgroup.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">732-933-2754</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 5P#A P$1  (1 0,1 ?_$ +T  0 # 0$  P$!
M       '" D*!@$"!00# 0$  @(# 0$              0(#! 8'" D%$
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M'V^86+.6\2CI_J[3R7C&#,R,IYR!B=;<:4,M2N2OXMV$[K4=Q"^?Q7EDA_\
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M%I5;@O?.?AN?T\GUXO*3"<: @-]IR#Y6[0,:D [.9N''ZA8V8((ANJ<Y9=H
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M[@%XV$.9E-E\UY9R'<JQC\T](URBUBFO/IK^4:02QV3F8F94Q5')R*NB&!%
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MYIW';+_:;V7;=SAEM]Q@>6R1R-+'L<,PYKJ$?\,0L/8FPW7%MFCK=7'3NKY
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M:BRJ6]$51^>7\'O(']W[[^MLM9(OQ!\U5WI7'15O^*&*-P 0'-&.=P'X#_\
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M_+WC5CB=+6[OF2E5Z7,J")FSR1$Q$3B<$]G#E!-5N@!3F #&,8"D_2$.NNW
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J"]ICI8'_ *CL6GYG3J3A86[GU!7],' %-OW@7X#JOS4X?56 T1-$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mbot-20221006.xsd
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa2EmbP9z5Z8yekhvWB3bfn6byUthhjzKiqIOkBWsYUF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:MBOT="http://microbotmedical.com/20221006" elementFormDefault="qualified" targetNamespace="http://microbotmedical.com/20221006">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://microbotmedical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20221006_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="mbot-20221006_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mbot-20221006_lab.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mbot-20221006_pre.xml
<DESCRIPTION>INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://microbotmedical.com/role/Cover" xlink:href="mbot-20221006.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140466276337808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  06,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MICROBOT
MEDICAL INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000883975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3078125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25
Recreation Park Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Unit
108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hingham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-3605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBOT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbot-20221006.xsd" xlink:type="simple"/>
    <context id="From2022-10-06to2022-10-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883975</identifier>
        </entity>
        <period>
            <startDate>2022-10-06</startDate>
            <endDate>2022-10-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-10-06to2022-10-06">0000883975</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-10-06to2022-10-06">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-10-06to2022-10-06">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-10-06to2022-10-06">2022-10-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-10-06to2022-10-06">MICROBOT MEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-10-06to2022-10-06">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-10-06to2022-10-06">000-19871</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-10-06to2022-10-06">94-3078125</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-10-06to2022-10-06">25 Recreation Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-10-06to2022-10-06">Unit 108</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-10-06to2022-10-06">Hingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-10-06to2022-10-06">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-10-06to2022-10-06">02043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-10-06to2022-10-06">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-10-06to2022-10-06">875-3605</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-10-06to2022-10-06">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-10-06to2022-10-06">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-10-06to2022-10-06">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-10-06to2022-10-06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-10-06to2022-10-06">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-10-06to2022-10-06">MBOT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-10-06to2022-10-06">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-10-06to2022-10-06">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !H1T=5JL0B%C,!   B @
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( &A'1U5ED'F2&0$  ,\#   3
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M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !H1T=5)!Z;HJT   #X 0
M&@              @ ',$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !H1T=599!YDAD!  #/ P  $P              @ &Q$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex10-1.htm</File>
    <File>ex99-1.htm</File>
    <File>mbot-20221006.xsd</File>
    <File>mbot-20221006_lab.xml</File>
    <File>mbot-20221006_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mbot-20221006_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbot-20221006_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mbot-20221006.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MBOT",
   "nsuri": "http://microbotmedical.com/20221006",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-10-06to2022-10-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://microbotmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2022-10-06to2022-10-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001493152-22-027872-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-027872-xbrl.zip
M4$L#!!0    ( &A'1U6>#:PW@U(  &D< @ *    97@Q,"TQ+FAT;>U]67/;
M6++F.R/X'S".Z0XI@J9WN]OV=5Q94G7IELOV2'+7U,,\@,2AA#((L+%09O_Z
MR?4L "C9U;(MRKP1M]J22. L>?+D\N67+W\^_?7-J^'@Y<^'>P?POQ'^W\O3
MH],WAZ]>WN/_A;_>DS^_?/WNX/?HY/3W-X?_=6=6Y/7SZ,']11V=IG-316_-
M171<S.-\Q+\812>F3&=WX(OPU??ZO=I\JN_&67J6/X^F)J]-^2*:Q^59FM^M
MB\7SZ+[]<5+4=3&'W]QY]?*G=V]/_3??G<7S-%L]O_S=+R+Z;)7^V_!0[[SZ
M:SZI%B]>WL,'PAS?MT;'LYH46?(94].1PA#AH_;_7T0TQ[J,\VI6E#"#9K$P
MY32NC/Q)IE^F9^>U_"K-$X.OOI_FUS?=[DCR(C=W7AU^.D\G:3T</+@_?G#%
M6GS^,LC^X6O;.]@WE#6+PC)Q6[=<)3[<\_&3Z]SU.Z_V3DX.3X>#]Q^.]W_>
M.SF,]OYQ?'CXZ^';TVO;Z_[YRR3_:*HZG:V^]BQ?OK9;^_K5=<[L"V9S>IY6
M$2UWU%WMX6"GQK_C0+/D7TWQXN71J[VSTI@Y/./EO:-7?RWYUS"!W0@^2=)A
MDBC-ZR**JZB81?2$IU$2K_"G=].ZF)AR%#V\__!A-%E%;],ZS8IB$;VID_$H
MBO/HJ"ICDZ7#09;.TQH>EJ7Q),W2>A5-B_DBSE?13C"B$Y-EINP,)\Z3Z-=T
M6A9PBJ-?39).XZSSENAS7_*^*:?G<!PZ[QGSEOV9#>MN2"">O=MXK0+X+4_3
M-]>(7U<9?-UKSFI?TA(@?J_CZ<>SLFCR!.7ONA7&39^][G?_S$_W7K\YC/8/
MW[PY>;^W?_3V'_]UY_X=^OG]WL&!_OS%JW.1)O4Y?O3^7U[ ]5HFIKP[+;(L
M7E0P<OW7'3([7YX>?_D+EJ:L42GI6H/Y<4>,V)>G!W]ZP/?'#Z_YHMJ)=^V:
MGQ[\)T/\RGJ!;P(>'RCK*#%+DQ4+4.]36.LXS?%BPL],ZP8N@T4)?RM!Y>-5
M49OI>5YDQ1EH_C2?9DV2YF=P>YGH?5R#U%=PP>7T\RPU8&L5L^?140Y2FS7S
M-(>GE6895],FB\OTWW&=%CF/ \:03F$6%VE]#B^:GA<E/G@.KXOSM)K3RW%8
M9V6,%]$<KZQI#"^"JS3:T1N(SL&I':.>!;F)=D=1..8#?NL+?]_@/\<W15J_
MXFUPHR6T.];;NBL[DPU5&FF.MQ"<1&ORH>&:UE6T++(FK^,2;$13573&\4^H
M1.B'[7&[:7O[ QVWZ88<-WNJ>(@7:74.WT=W<?JO)BU-%&<91Y;@(75:9\;>
MD*6I:KV$]ZK*P)'<@0-;-=-S&'4Y1P\T,;,TA\,[@8O_8O<%?O='V/[MH;R)
MN[*3;,BA].] =R(K^"W^KSVR(SJ*[EYT'UW([Z)96<PC?MS('>5U)YD,[\([
MT&C'\C"F<)^FB=RL,.*2/K6(5QA[PL@1F>9V*/(4?C/'G0Q,?A5G=6I83X2J
M8=PO@/?(F_R3 9UM-.1:)O3VW6^CX>#TY\/CPY_>'1^B3+3$0?9W49IY6L&S
M28[@%]-B:?(8G#7Z36G@ Q6,D*TSD.<:!0G\L'.0P#1G<4;1*N#+9716% G]
M:@E.73S)3/A6&!.^HS13D\+*X >K9C9+IZG)IQ3=O#A/X2J*X1+#%X",QM./
M>7&1F>3,)",1X)($$C\ ,JN?PZ J!DQG10;"63V_-;MY:72G7W)=/,>/W[3C
M.Z_?'1\<'ONAG2!@\UDIG2_) 7I7T]H+QU/MO<ML(S37&J#YC #:@W$G>";W
MT>5#_J:#/$#]G-)1[1NMZ&BGH6_QP?B<L.<US?S1D_'C)]\BV1 DD>BR]U(I
MN*^O7\T-+ 99#:!,^2K_:UGAW\'(B/.S=.)L"/NC. *LPNOSF/V#PT\8#H/;
MGE\5!,A SV9I55.>*GKY0=/)T1Z.XL,K35K93-=(WJG?GS1UE!>US1VA\P)C
M/O)CB^]M;+&JBFE*H;U:E+X77Z2H(%Q2"_B:VC NRC<<Z,4F\;P>.V:71X<#
MD%#CB%)816[T'ER41=+ \TN3<8@1_ENF<59Y(\&GH$T5U]$%C#*Z*,J/N#SP
M75B&JH+++YWA9W;'T4]P8TXQS@G3 \-O453X4L\KJ\YQ./""0E;-R/@JD*XH
M*>,+>"-\Q< >YL900'269O@4&2O9?/@;FD!BZAA^2+R_\M+@YL\GV0I>4]4E
M_Z6R\Y3U/-!ET77RMJ0T9PU\N"A7L&H9J!]0ZZ-U.PE?_S][.E!8&Q-/SX<#
M/+$C[^H7!Q56!9:E\JP5L4WA,?=@ 1M0*B6%E<#(J,LB@[V=8<BW-'%5Y&1^
MI#FZQ"O/5MW,L_]5+=3OHL!$ICH:K#0SYXRP,8?"+7);1;#QBP+3"2GG'_BW
M<$@*.$9H9DK\WNF J+B@P[YR7A6="#Q*),+V+R#7SX<#&>/;8AGOER"#,KQ1
MU/Y#]']K,)^-_)V>VOG(Z]-?[/?I](".,#GHV"DI1EBM>9&D8 *+A4UZ<@[S
M6O+?R6(N33';= G^:EB-[R[(:37-BJHIS7!P,CTW29,93ZHC=RW3W3!K4'_"
M+N,5DYG:T$V*&LY\FII%1_^V+O&V1X9/NHA+L('0*0(9 XEQ7AIHTA/#=\'3
MZ/;+$<SF?]V]&_V$Z<7GT?OXS+R Y_RK >\2OO\DNGM7(T@'1__4T;3<FJ<X
M!TE6Z^]>9^"&1@_&,+^H*K(T@6%\GH\E[UB;_&XER;NSO=1G"A<[,S/Z1J\[
MHK S[W7N5E'?0#V#E_=@?7J6:@(WZ\>[$P/"!2-<T/KZ;N)3'O*/LC*>K-U#
M86/YND:7:JM_K]*_ZJ0,!VPX>[BRB)7N3KI+)BN8V^F\LF%0,#/ ?D1K8EJ:
M)"4%7,>?Q%S6:!9(5H[7,)@:TW.8L*DX2 7*&?X4@?G08+ZE3"MU18:#EB\B
M!CV^%X<![XC &$Z+1$R9DO6XW/)@&Y!7@S8O_!4^9VVA?;ADX$\O8$8R)1XE
M3PR,[[BI>'SQ5()MTW-T+"A,S+^2M!!^J#08ZBO9*'>_AL$6LQD]!2R5C^"X
M^WZ??$XGS!:X?_VTKB?\;F+F&),P%3L<9TV,GS8PKGD,;@T87Q7X[5EJ2AJ
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M2 TFOL5VBCDIW[*' K3>:6^%5=^M:-]0Q1E;:*"U35Z1C:=0B%Y#B^R^:CA
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M>]&HIRH8(L4#4S&,]4XER%]DC5@7LS6B9H]!P,XT6S>QD9 MRP=S[@@T0;O
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M7NYK3G7@(8ME:O58NQZ&N^$AJ;)>W\.!>P.8"0]&3^Z3I6"3QMVN$Q8N(\L
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M3KYG.D/*66X;^[G41_;I_ J?K1,LG,HR<5^(Q'F48HD1Y,>$4DKA:L2H&@X
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MC5WA]34=,F."68G1CX]VJN4GC*#!B,\Q8+8 QE_WL1A]U\>$M6#D+I#&Y+M
MGI;%OK6(+/8;O%].LZ/.=YHV,1TJY2LX-S"',3%V%S(F@EJQKWS=;S<\9T.^
M68W()!ZV%C)+<)\L.4E8M$8#@@.(PI,!S"_S 8JY"VM*@E^X(/:-?$-!SI1
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M@[9XIM0+$3,Q,G&<SFE,=K^0/=@N0^>6"<!F&PI-%! 5=F< %I48%6HDY%[
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MY^ @1$KI&(([3B2$1'1$\1*@3"S$;Q\>K+-]E]@5%/V&%1RP,@A(>NWIL(B
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MW\ZI:QIW9O*YFU#6=13<AQQ'CL+^\SUOZ&JBC2*Q*6OB9$)Y7O]W:W-@TFW
MJY+$HZVQVJE]BT.?=F-WI>)(JH0JR[JLBZAX+V+'W71CT5T092MJQW/&M\&>
M*IGZZ&Q(2(^CNZ!L$\W0O++M)\Z'(2>S:IP')D">/0R@E6JPB+ZG.E9LX;C4
M@-VS!/+MH_*MT-8PYO+<>: SYOQUKKB++W4'P^."IP@0_"GF2!%4BQ2!*R$R
MPA_H0JH:\/N60-Z_8?*NTH:$^>^,*$,57T-('QD#8?^."=NC$(GWHR)",\<'
M OS8&DC\#>J-AT<C$O+QG'+N$CHB0+V\RAZ(_0],['Z=KP#\S;.[OMM+"YS]
M3A$@_C]?"_XCM4@1N*>*R<1>TA6 _9$QD/H9)G6/0E3>-R*!TMZ:@O,??-@'
M\I!0#YF."2\\&MIC.HR[PAR*'"7GK)6)BOU?2A08^HXQ%#E*&EHCL6'@@TRI
M/6>"HXK?&HH<)0&M$]DP\QMAF%F[&8#/63KY\>!TG_6Q%90Q2M+I$X7"MGS2
M((R;V CQ/;2$,D;)-4/B4#@/K!Y%^$@D=/61KD.@CTRAI%%RS* \%-3WBJ5$
MK<<LKA\TCFVAL%$RR[! %-J/9#5*K"HV9<748#UT;Q$H>Y2T$B07)00C$4NU
MD#N/BP<RL^?C>B"3X)!>4Q :#I1\\P7248)RE206E][\N66"]D*AJ#0'SQ'A
M!2 @\Y5@[[\,>Q^.'24/K97Y2K"?O@S[*1P[2BY:*Q,3^\!^O%./<NF9@?8:
M0Y&CY*(U$C&!YU>:.W6OY#,K5DC543\J 46/F**&Q:)V^.(B#^GMI264-V*Z
M6BT.D_.]U(;P_]BB[DZRVA[*'#%Q#0EM^@%C$7?WT,*WE.C !,H7)5>ME-,T
M4A=A18F_^^Y;0(&B)*!58AKF>2O=W,=<BN#SV&,K*%>43-(GJNF!UZTGUMY3
M?^=K\ HVE&'U4$;#&+\I9JP' YFFF=@\H_',BGE,H7A1TK^@O(91CR5G,3-,
MS#[9.T3%"*_F7&4'A8R2[/F%-4SX7E$7:6ION_-U7&[#@;J;3GTC;\@>2APE
MUZL7BDM^I'5&U4OY5Y2"1@$E[8.*;GJ<H7%FA[UUKS]Y=#MF/*/,D164-4K*
MYQ/5,-O/\E$1MW-OO$XGDONWAU0:0@FC)'@!:0U#WO.C&N^!"10L2F97*0=I
M3+A9Q7,B9M2_>J':$@H8)=,+B4,;>V>@L7?VPK$7)>/SB4)B6ZP-MV?4W82S
M&?'O) L6 .^SP20>D-KT_KU\RX_;TZW2W(^A_5"-W6,*!8ZS13(DKVG46<(,
M30J7ADP0$=N4:KNOS9.=UY>"!@!G#R50-,KC_6^4\X]"+L68$BT%38I;_= 3
M?F\1:!00YQ!KY**$X*ODF:6D\H6@RG,.>$RAR!'G#CWR<-9>%HN:M]>>XN4=
M(>*^$E#PB).(8;%(Z],,=3ZS9_J>&++Q,,3?5P+*'W%",2P6;?V\&M@+STR&
MY\P/#*&T$9?"5DI#@3Q.">?7F6:"ZN#8<F (A8RXYK52&@KDFY2JF1W4/BBY
M-//-WLX0;$\!*'3$E:U!J3CP5S_VD1?[WX+D*ZS!;R= Q.X5B?7:C3AV"RF*
M*[E(B/)0#]E#N:-NK/0+;9C\G9E3M7O_E#LSLGE;:-%#?2EH%%#25:AHG&OK
MSD[^X*5USP[*&S$QK1*&LV<JFW 6#[DDP?OR/3,H7\0LM$(6"MYK(IY4MC#Q
M^E[)F%(W?:*W9QL@(0)6  T)8G[Z(A0XCPMDFKK-1#)^&L^M:'V7F?Q=IM:_
MX$.#8#EH:# W<0*$(]T%Z1\;O6ARO7Z@4ZK<,H5'NC+7MJ&G\$T1H#@T/JAO
M% )CJ C31?=(UZT]X-Y66WSC?KDWLMHC_P-02P$"% ,4    " !H1T=5G@VL
M-X-2  !I' ( "@              @ $     97@Q,"TQ+FAT;5!+ 0(4 Q0
M   ( &A'1U47.=F %PT  (8W   *              "  :M2  !E>#DY+3$N
M:'1M4$L! A0#%     @ :$='598A>U]C&0  ",<   L              ( !
MZE\  &9O<FTX+6LN:'1M4$L! A0#%     @ :$='529JOW]4 P  S@P  !$
M             ( !=GD  &UB;W0M,C R,C$P,#8N>'-D4$L! A0#%     @
M:$='51H$"V;]"@  @(8  !4              ( !^7P  &UB;W0M,C R,C$P
M,#9?;&%B+GAM;%!+ 0(4 Q0    ( &A'1U5<F5E\6P<  .-7   5
M      "  2F(  !M8F]T+3(P,C(Q,# V7W!R92YX;6Q02P4&      8 !@!N
) 0  MX\

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
